Immunotherapy plus radiation after surgery for advanced UTUC
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove your kidney and ureter for cancer in the renal pelvis or ureter. The cancer was stage pT3-4 or had spread to lymph nodes (N+).
- Your kidney function is low (eGFR below 60) or you cannot have chemotherapy due to other health reasons.
- You are between 18 and 80 years old.
- You have had a CT scan of your abdomen and pelvis within the last 4 weeks before joining the trial.
- You have not had other cancers in the last 5 years (except certain skin or breast cancers).
- You are willing to attend all study visits and sign a consent form. Your overall health is good (KPS score above 70) and your blood counts are within normal ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
This trial tests whether giving radiation therapy before surgery can improve outcomes for people with high-risk upper urinary tract cancer. It aims to see if this approach is safe and effective.
This trial tests a combination of two drugs and radiation therapy given before surgery for high-risk upper tract urothelial cancer. The goal is to see if this approach can improve outcomes for patients who are eligible for surgery.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
This study tests whether combining two drugs—toripalimab (an immunotherapy that boosts your immune system) and 9MW2821 (a targeted drug that delivers treatment directly to cancer cells)—before surgery helps shrink tumors and improves outcomes for people with upper tract urothelial cancer. The goal is to see if this combination is safe and effective before the kidney and ureter are removed.
Hear when a new Ureter Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.